TITLE

FDA urges "black box" warning on pediatric antidepressants

AUTHOR(S)
Wayne, Kondro
PUB. DATE
October 2004
SOURCE
CMAJ: Canadian Medical Association Journal;10/12/2004, Vol. 171 Issue 8, p837
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports that a blue-ribbon scientific advisory panel has urged the U.S. Food and Drug Administration (FDA) to include "black box" warnings on selective serotonin reuptake inhibitors (SSRI). Other demands of the panel to the FDA; Reason of FDA epidemiologist Andrew D. Mosholder for recommending a ban for SSRI; Information on an August 16, 2004 memorandum written by Mosholder.
ACCESSION #
14606405

 

Related Articles

  • NEW INDICATIONS.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p78 

    Reports on the U.S. Food and Drug Administration's approval of Paxil CR's controlled-release selective serotonin reuptake inhibitor and Novartis Pharmaceuticals' oral antidiabetes agent Starlix for drug indications.

  • Medical Research To Die For. O'Meara, Kelly Patricia // Insight on the News;10/15/2002, Vol. 18 Issue 38, p22 

    Presents the results of a study conducted by Arif Khan, medical director of the Northwest Clinical Research Center, on serotonin selective reuptake inhibitor (SSRI) antipsychotic drugs. Incidence of suicides and attempted suicides in the clinical trials for SSRI antidepressants; Reaction of the...

  • Dapoxetine. Feret, Brett // Formulary;Jul2005, Vol. 40 Issue 7, p227 

    Dapoxetine (Alza/Ortho-McNeil) is a novel oral medication undergoing FDA review for premature ejaculation, one of the most common disorders of sexual dysfunction in men. Dapoxetine is a fast-acting inhibitor of the serotonin reuptake transporter. It has a short half-life and is structurally...

  • Citations and Clinicians' Notes: Suicide. Khan, A.; Khan, S.; Kolts, R.; Brown, W.A.; Dwivedi, Y.; Rao, J.S.; Rizavi, H.S.; Kotowski, J.; Conley, R.R.; Roberts, R.C.; Tamminga, C.A.; Pandey, G.N. // Current Medical Literature: Psychiatry;2003, Vol. 14 Issue 3, p76 

    Presents abstract of several studies on suicide. Analysis of the U.S. Food and Drug Administration on suicide rates in clinical trials of selective serotonin reuptake inhibitors (SSRI), other antidepressants, and placebo; Characteristics of cyclic adenosine monophosphate.

  • FDA APPROVES DESVENLAFAXINE SUCCINATE FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER. J. C. // Primary Psychiatry;May2008, Vol. 15 Issue 5, p25 

    The article reports on the approval of desvenlafaxine succinate, a serotonin norepinephrine reuptake inhibitor, by the U.S. Food and Drug Administration to treat adult patients with major depressive disorder (MDD). Accordingly, its efficacy was established through four, 8-week randomized,...

  • Milnacipran: An SNRI for fibromyalgia.  // Pharmacy Today;Mar2009, Vol. 15 Issue 3, p25 

    The article reports on the efficacy of milnacipran, a selective serotonin and norepinephrine reuptake inhibitor, for fibryomyalgia in the U.S. The drug has been approved by the U.S. Food and Drug Administration for management of fibromyalgia and has been licensed for the treatment of depression...

  • Escitalopram treatment for premature ejaculation has a negative effect on semen parameters. Koyuncu, H; Serefoglu, E C; Yencilek, E; Atalay, H; Akbas, N B; Sarica, K // International Journal of Impotence Research;Nov/Dec2011, Vol. 23 Issue 6, p257 

    The aim of this study was to determine the impact of long-term escitalopram treatment on semen parameters of patients with lifelong premature ejaculation (PE). Between November 2008 and January 2010, patients admitted to urology outpatient clinic with a self-reported complaint of PE were...

  • Safety Problems Roil Pharma and FDA. Wechsler, Jill // Pharmaceutical Technology Europe;Dec2004, Vol. 16 Issue 12, p19 

    This article reports that the last few weeks have been disastrous for the pharmaceutical industry and federal regulators. First, experts decided that safety data does indicate that antidepressants may cause serious problems for young patients and warrant black box warnings. Then, Merck & Co....

  • Neonatal behavioral complications from SRI exposure: fairly common, rarely serious. Schwenk, Thomas L. // Archives of Disease in Childhood;Sep2005, Vol. 90 Issue 9, p980 

    This article focuses on neonatal behavioral complications due to serotonin reuptake inhibitors (SRI) exposure. Use of SRIs during pregnancy is not associated with Fetal anomalies, but concerns about behavioral signs led the U.S. Food and Drug Administration to require labels warning about...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics